Truist Financial Corp Cardiff Oncology, Inc. Transaction History

Truist Financial Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$2.11 - $7.25 $270,048 - $927,891	-127,985 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $167,909 - $234,684	-32,415 Reduced 20.21%	127,985 $769,000
Q3 2021 Nov 05, 2021	SELL	$5.01 - $7.58 $460 - $697	-92 Reduced 0.06%	160,400 $1.07 Million
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $273,261 - $412,563	41,092 Added 34.42%	160,492 $1.07 Million
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $40,040 - $86,108	4,400 Added 3.83%	119,400 $1.11 Million
Q4 2020 Feb 18, 2021	BUY	$12.02 - $24.71 $1.38 Million - $2.84 Million	115,000 New	115,000 $2.07 Million

125

25.3M

866K

203K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $163M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.